Search In this Thesis
   Search In this Thesis  
العنوان
Comparative analysis of coagulation factors FV, FVIII and fibrinogen activity in fresh frozen plasma, frozen plasma, cryoprecipitate and cryosupernatant
المؤلف
El Sayed,Walaa Hamza Ahmed
هيئة الاعداد
باحث / ولاء حمزة أحمد السيد
مشرف / الأستاذ الدكتور/ إبراهيم يوسف عبد المسيح
مشرف / المدرس/ سهى أحمد أبو العلا
مشرف / المدرس/ سهى أحمد أبو العلا
الموضوع
Coagulation factors FV FVIII cryoprecipitate fresh frozen plasma cryosupernatant
تاريخ النشر
2018
عدد الصفحات
81 P.
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
أمراض الدم
تاريخ الإجازة
1/1/2018
مكان الإجازة
جامعة عين شمس - كلية الطب - الباثولوجيا الإكلينيكية والكيميائية
الفهرس
Only 14 pages are availabe for public view

from 81

from 81

Abstract

Studies proved that storing whole blood overnight at 4°C resulted in a decrease in the activity of coagulation factor FVIII, without significant loss of activity of coagulation factors FV or fibrinogen. This study is conducted to compare the activity of labile factors V and VIII as well as fibrinogen level in FFP with that of FP24 and to assess their levels in cryoprecipitate and cryosupernatant bags as well.
Plasma is a crucial component of blood with albumin, coagulation factors and immunoglobulins being the most important components of plasma that can be transfused. There are many types of plasma such as fresh frozen plasma (FFP), plasma frozen within 24 h, single donor plasma, cryoprecipitate, cryoprecipitate - reduced plasma, pathogen inactivated plasma, and thawed plasma. FFP is human donor plasma frozen in a short period after the process of collection (often 8 h). Plasma frozen at later intervals (up to 24 h) after collection is referred to as frozen plasma (FP24).
Cryoprecipitate is a frozen blood product prepared from thawed FFP and contains fibrinogen, Von Willebrand factor (vWF), FVIII, FXIII and fibronectin. It’s used for treating patients with inherited or acquired hypo- or dysfibrinogenemias. It should no longer be the first choice in treating hemophilia A or von Willebrand disease given the widespread availability of recombinant or virally inactivated factors. Cryoprecipitate is prepared by thawing a unit of fresh frozen plasma in 1 to 6°C and then the cryoprecipitated material is separated from the liquid plasma. The cryoprecipitate is then frozen and stored at temperatures not exceeding -18°C for up to 1 year.
The current regimen for the preparation of FFP within 8 hours of whole blood collection was implemented to maintain the activity of coagulation factors. When whole blood is stored at 4°C for short time intervals, factor VIII significantly decreases in the extracted plasma, while other coagulation factors keep unchanged. A few studies have analyzed the stability of different coagulation factors when whole blood storage time is prolonged to 24 hours and compared this to FFP. The data available on the levels of coagulation factors (factor VIII, vWF, fibrinogen, and other proteins) in cryoprecipitate made from whole blood stored for 24 hours before component preparation is not enough .